IGKV2D-29 and glaucoma: An alternative and complementary pathway by which α2A agonists reduce Aβ expression in OHT, may be via oxidative stress modulation.26 Oxidative stress reduces expression of sAPPα and α-secretase activity71 and is implicated in the pathogenesis of glaucoma, where an ischaemic element is well-recognised.72 The observation that BMD increases sAPPα and reduces Aβ levels in RGCs when exposed to a hypoxic insult (CoCl2) supports evidence for α2A agonist's neuroprotective activity under oxidative stress.